2,434,783 AMERICAN DEPOSITARY SHARES EACH REPRESENTING 40 ORDINARY SHARES, NO PAR VALUE PER SHARE BIONDVAX PHARMACEUTICALS, LTD. UNDERWRITING AGREEMENTUnderwriting Agreement • February 2nd, 2021 • BiondVax Pharmaceuticals Ltd. • Biological products, (no disgnostic substances) • New York
The undersigned, BiondVax Pharmaceuticals, Ltd., a company incorporated under the laws of Israel (collectively with its Subsidiaries (as defined below), if any, the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (the “Underwriter”) on the terms and conditions set forth herein. The Underlying Ordinary Shares (as defined below) are to be deposited pursuant to a deposit agreement, as amended, dated May 11, 2015 (the “Deposit Agreement”), among the Company, The Bank of New York Mellon, as depositary (the “Depositary”), and holders and beneficial holders from time to time of the ADRs (as defined below) issued by the Depositary and evidencing the ADSs (as defined below). Each ADS represents 40 Ordinary Shares (as defined below) deposited pursuant to the Deposit Agreement.
